[Pandemic influenza A in the ICU: experience in Spain and Latin America. GETGAG/SEMICYUC/(Spanish Working Group on Severe Pandemic Influenza A/SEMICYUC)].
BACKGROUND
Pandemic Influenza A (H1N1)v infection is the first pandemic in which intensive care units (ICU) play a fundamental role. It has spread very rapidly since the first cases were diagnosed in Mexico with the subsequent spread of the virus throughout the Southern Cone and Europe during the summer season.


OBJECTIVE
This study has aimed to compare the clinical presentation and outcome among the critical patients admitted to the ICU until July 31, 2009 in Spain with some series from Latin America.


METHODS
Six series of critically ill patients admitted to the ICU were considered. Clinical characteristics, complications and outcome were compared between series.


RESULTS
Young patients (35-45 years) with viral pneumonia as a predominant ICU admission cause with severe respiratory failure and a high need of mechanical ventilation (60-100%) were affected. Obesity, pregnancy and chronic lung disease were risk factors associated with a worse outcome, however there was a high number of patients without comorbidities (40-50%). Mortality rate was between 25-50% and higher in the Latin America series, demonstrating the specific potential pathogenesis of the new virus. The use of antiviral treatment was delayed (between 3 and 6 days) and not generalized, with greater delay in Latin America in regards to Spain.


CONCLUSIONS
These data suggest that a more aggressive treatment strategy, with earlier and easier access to the antiviral treatment might reduce the number of ICU admissions and mortality.
Rodríguez
A
A
Unidad de Cuidados Intensivos, Hospital Joan XXIII, CIBER Enfermedades Respiratorias, IISPV, Tarragona, España. ahr1161@yahoo.es
Socías
L
L
Guerrero
J E
JE
Figueira
J C
JC
González
N
N
Maraví-Poma
E
E
Lorente
L
L
Martín
M
M
Albaya-Moreno
A
A
Algora-Weber
A
A
Vallés
J
J
León-Gil
C
C
Lisboa
T
T
Balasini
C
C
Villabón
M
M
Pérez-Padilla
R
R
Barahona
D
D
Rello
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use; D015897:Comorbidity; D004196:Disease Outbreaks; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000302:isolation & purification; D007251:Influenza, Human / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology; D007362:Intensive Care Units / Q000706:statistics & numerical data; D007843:Latin America / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D053139:Oseltamivir / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology / Q000821:virology; D012042:Registries; D012121:Respiration, Artificial / Q000706:statistics & numerical data; D012131:Respiratory Insufficiency / Q000209:etiology / Q000628:therapy; D012720:Severity of Illness Index; D012769:Shock / Q000209:etiology; D013030:Spain / Q000453:epidemiology; D055815:Young Adult
D000998:Antiviral Agents; D053139:Oseltamivir